Please check your internet connection and try again.
**Mega%2525252525252525252525252525252525252525252520cv (Megestrol Acetate)**
## Overview
Megestrol acetate is a synthetic derivative of progesterone. It is a potent progestin with antineoplastic and appetite-stimulating properties.
## Primary Indications
* **Oncology:** Treatment of advanced breast cancer (palliative) and advanced endometrial carcinoma.
* **Cachexia/Anorexia:** Management of anorexia, cachexia, or unexplained significant weight loss in patients with acquired immunodeficiency syndrome (AIDS) or advanced malignancy.
## Adult Dosing
* **Breast Cancer:** 160 mg orally once daily.
* **Endometrial Carcinoma:** 40 mg orally four times daily (40 mg QID) or 160 mg orally once daily.
* **Anorexia/Cachexia (AIDS/Malignancy):** 400-800 mg orally once daily.
## Pediatric Dosing
There is no established pediatric dosing for megestrol acetate.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustments are recommended, but caution is advised.
* **Hepatic Impairment:** No specific dose adjustments are recommended, but caution is advised.
## Contraindications
* Known hypersensitivity to megestrol acetate.
* Pregnancy.
* Undiagnosed abnormal vaginal bleeding.
## Adverse Effects
* **Common:** Weight gain, increased appetite, nausea, vomiting, diarrhea, abdominal pain, rash, hot flashes, dyspnea, edema, hypertension, amenorrhea, vaginal bleeding.
* **Serious:** Thromboembolic events (deep vein thrombosis, pulmonary embolism, stroke), adrenal insufficiency, hyperglycemia, Stevens-Johnson syndrome, toxic epidermal necrolysis.
## Key Drug Interactions
* **Aminoglutethimide:** May decrease megestrol acetate levels.
* **CYP3A4 Inducers (e.g., rifampin, phenytoin, carbamazepine):** May decrease megestrol acetate levels.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole):** May increase megestrol acetate levels.
* **Oral Antidiabetic Agents:** May affect glycemic control.
## Monitoring
* Weight and appetite.
* Signs and symptoms of thromboembolic events.
* Electrolytes (especially potassium).
* Blood glucose.
* Adrenal function if used long-term and withdrawn abruptly.
* Signs of hypersensitivity reactions.
* Vaginal bleeding.
## Clinical Pearls
* Due to its potent progestogenic activity, avoid its use in pregnant patients.
* Weight gain is a common and often desired effect in cachexia management, but it may be accompanied by fluid retention.
* Monitor closely for thromboembolic events, which are a significant risk.
* Adrenal insufficiency can occur with abrupt discontinuation, especially after long-term use; consider gradual tapering if necessary.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any therapeutic decisions.
